International journal of antimicrobial agents · 2026
Population pharmacokinetics of total and free ceftriaxone in critically ill and non-critically ill hospitalised adult patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Setiawan Eko, Gonzalez Alvaro, Wölky Saskia A, Cotta Menino Osbert, Liu Xin, Sosilya Hernycane, Maresco-Pennisi Diane, Novy Emmanuel, Ordonez Jenny, Lukas Dwi Lily, Wallis Steven C, Xie Jiao, Roberts Jason A, Abdul-Aziz Mohd H
Аннотация
OBJECTIVE: To characterise the population pharmacokinetics of total and free ceftriaxone in critically ill and non-critically ill Indonesian patients, define optimised dosing regimens against common hospital pathogens implicated in severe pneumonia and complicated urinary tract infections (UTI), and compare these findings with published data to support broader applicability.
METHOD: This study recruited critically ill and non-critically ill adults receiving intravenous ceftriaxone. Serial plasma samples were collected over one dosing interval. Total and free ceftriaxone concentrations were measured using a validated UHPLC-MS/MS method. Population pharmacokinetic analysis was performed using Monolix. Dosing simulations were performed to assess the probability of efficacy (100%fT>MIC for a given MIC) and toxicity risk (total trough concentration >100 mg/L) on days 1 and 3 of therapy. Fractional target attainment was evaluated using EUCAST MIC distributions for common pathogens implicated in severe pneumonia and complicated UTI.
RESULTS: Fifty-three patients were recruited (median age, 57 years [IQR 39-65]; median eGFRCKD-EPI 67 mL/min/1.73 m2 [31.4-92.3]; 26 males; 42% ICU). A two-compartment model with complex protein binding best described the data with eGFRCKD-EPI as the primary determinant of clearance. Once-daily intermittent infusion regimens (1 and 2 g every 24 h) failed to achieve optimal efficacy targets in patients with preserved or augmented renal function (eGFRCKD-EPI ≥60 mL/min/1.73 m2).
CONCLUSION: A simplified renal function-stratified dosing strategy provided the best balance between safety and efficacy for empirical treatment; 1 g every 24 h for patients with eGFRCKD-EPI ≤60 mL/min/1.73 m2 and 1 g every 12 h for patients with eGFRCKD-EPI >60 mL/min/1.73 m2.
METHOD: This study recruited critically ill and non-critically ill adults receiving intravenous ceftriaxone. Serial plasma samples were collected over one dosing interval. Total and free ceftriaxone concentrations were measured using a validated UHPLC-MS/MS method. Population pharmacokinetic analysis was performed using Monolix. Dosing simulations were performed to assess the probability of efficacy (100%fT>MIC for a given MIC) and toxicity risk (total trough concentration >100 mg/L) on days 1 and 3 of therapy. Fractional target attainment was evaluated using EUCAST MIC distributions for common pathogens implicated in severe pneumonia and complicated UTI.
RESULTS: Fifty-three patients were recruited (median age, 57 years [IQR 39-65]; median eGFRCKD-EPI 67 mL/min/1.73 m2 [31.4-92.3]; 26 males; 42% ICU). A two-compartment model with complex protein binding best described the data with eGFRCKD-EPI as the primary determinant of clearance. Once-daily intermittent infusion regimens (1 and 2 g every 24 h) failed to achieve optimal efficacy targets in patients with preserved or augmented renal function (eGFRCKD-EPI ≥60 mL/min/1.73 m2).
CONCLUSION: A simplified renal function-stratified dosing strategy provided the best balance between safety and efficacy for empirical treatment; 1 g every 24 h for patients with eGFRCKD-EPI ≤60 mL/min/1.73 m2 and 1 g every 12 h for patients with eGFRCKD-EPI >60 mL/min/1.73 m2.